首頁 > 市場調查報告書 > 醫療設備

導管

市場調查報告書

商品編碼

1439428

藥物洗脫支架-全球市場回顧、競爭格局、市場預測（2030年）

Drug Eluting Stents - Market Insights, Competitive Landscape, and Market Forecast - 2030

出版日期: 按訂單生產 | 出版商:

DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

簡介目錄圖表

全球藥物洗脫支架市場規模預計到2023年將達到25.7億美元，到2030年將達到40.8億美元，2024-2030年預測期間複合年增長率為8.09%。

藥物洗脫支架市場動態

藥物洗脫支架市場的顯著驅動因素之一是生活型態相關疾病的盛行率不斷上升，這些疾病也導致心血管疾病的發展。糖尿病和高血壓是與心血管疾病的發展相關的兩種最常見的症狀。根據國際糖尿病聯盟引用的數據，到2022年，近5.37億20歲至79歲的成年人將患有糖尿病。同樣，世界衛生組織 (WHO) (2023) 提供的另一個資料集估計，平均有 260 萬人死於膽固醇升高。高膽固醇和血糖水平極大地影響供應心肌的血管系統，增加心血管疾病的可能性。藥物洗脫支架不僅用於疏通阻塞的血管，還可將藥物輸送到支架置入部位以避免再狹窄。因此，由於生活方式相關疾病的迅速增加，心血管疾病的患病率不斷上升，將推動對此類支架的需求，進而推動預測期內（2024-2030年）全球藥物洗脫支架市場的增長.預期帶來。

推動藥物洗脫支架市場成長的另一個主要因素是老年人口的增加。根據世界衛生組織（WHO）《健康老化十年（2020-2030）報告》 "Decade of Healthy Ageing (2020-2030) Report" 提供的數據，60歲及以上人口將從2019年的10億增加到2030年的10億，成長34%。這將增加到14億人。報告進一步指出，到2050年，世界老年人口將增加一倍，達到21億。老化與血管增厚有關，進一步影響血管彈性。這是老年人動脈硬化的主要原因，以藥物洗脫支架治療。因此，由於老化對脈管系統的影響，老年人口的增加預計將進一步推動對藥物洗脫支架的需求，從而在不久的將來推動藥物洗脫支架市場的成長。

然而，頻繁的產品召回和設備相關併發症可能會限製藥物洗脫支架市場的成長。

藥物洗脫支架市場報告稱，由於封鎖是打破 COVID-19 傳播鏈的必要措施，因此短期內市場成長受到限制。封鎖的實施對供應鏈產生了重大影響，生產中斷影響了設備的生產。許多國家根據緊急醫療需求將醫療程序分開，並暫停了各種被認為是選擇性的醫療程序，以在 COVID-19 危機期間簡化工作流程。因此，產品需求低於正常水準。然而，隨著包括醫療產業在內的各產業活動的恢復，2024-2030年預測期內藥物洗脫支架市場的情況正在變得有利。

藥物洗脫支架細分市場分析

在藥物洗脫支架市場的塗層部分，預計在預測期內（2024-2030年），聚合物塗層類別將在藥物洗脫支架市場中實現顯著的收入成長。這可能是由於聚合物塗層藥物洗脫支架的優點。這些支架上塗覆的聚合物會釋放抗增生藥物，抑制內膜增生並防止支架放置後再狹窄。此外，藥物洗脫支架上的生物可吸收或生物可降解聚合物比不可生物降解的聚合物更有益。可生物降解的聚合物塗層可以改善動脈癒合，因為它在藥物完全釋放後自行降解，留下惰性金屬支架。與第一代藥物洗脫支架相比，可生物降解的聚合物塗層也具有較低的晚期血栓形成風險。因此，考慮到與用於藥物洗脫支架的可生物降解聚合物塗層相關的好處，該產品類別預計將在預測期內產生可觀的收入並促進全球藥物洗脫支架市場的整體成長。

本報告提供了全球藥物洗脫支架市場的研究和分析，包括市場規模和預測、驅動因素和挑戰以及公司和產品概況。

藥物洗脫支架市場的驅動因素
- 心血管疾病患病率增加
- 老年人口增加
- 與生活方式相關的疾病盛行率不斷上升
- 越來越重視新產品開發
藥物洗脫支架市場的限制與挑戰
- 頻繁的產品召回
- 與設備相關的併發症
藥物洗脫支架的市場機會
- 提高產品安全性
- 推出針對新興國家的產品

第五章藥物洗脫支架市場波特五力分析

第六章 COVID-19對藥物洗脫支架市場的影響分析

第七章藥物洗脫支架市場佈局

按類型
- 冠狀動脈支架置放術
- 外周支架置入術
按腳手架（鷹架材質）
- 鉑鉻
- 鈷鉻合金
- 鎳鈦諾
- 其他
透過塗層
- 聚合物基塗料
- 無聚合物塗層
依藥物類型
- 依維莫司
- 紫杉醇
按最終用戶
- 醫院
- 門診手術中心
- 專科診所
按地區
- 北美
- 歐洲
- 亞太地區
- 其他地區

第八章藥物洗脫支架市場：全球公司份額分析－3~5家主要公司

第九章藥物洗脫支架市場公司及產品概況

Abbott
Medtronic
Boston Scientific Corporation
B. Braun Melsungen AG
BIOTRONIK
Cook
Terumo Corporation
Lepu Medical Technology (Beijing) Co., Ltd
Microport Scientific Corporation
Balton Sp.z.o.o
ENDOCOR GmbH
Eurocor Tech GmbH
Alvimedica
Biosensors International Group
Meril Life Sciences Pvt. Ltd
Translumina
Sino Medical Sciences Technology Inc
iVascular S.L.U
Sahajanand Laser Technology Limited (SLTL Group)
Cardionovum GmbH

第10章 KOL觀點

第十一章專案方法

第 12 章. 關於 DelveInsight

第十三章免責聲明與聯絡我們

簡介目錄圖表

Product Code: DIMDCL0231

Drug-Eluting Stents Market By Type (Coronary Stenting And Peripheral Stenting), By Scaffold (Platinum-Chromium, Cobalt-Chromium, Nitinol, And Others), By Coating (Polymer-Based Coating [Biodegradable And Non-Biodegradable] And Polymer-Free Coating), By Drug Type (Everomilus, Paclitaxel, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Specialty Clinics), by geography is estimated to register growth at a remarkable CAGR forecast during 2024-2030 owing to increase in aging population and growing prevalence of cardiovascular diseases

Global drug-eluting stents market was valued at USD 2.57 billion in 2023, growing at a CAGR of 8.09% during the forecast period from 2024 to 2030 to reach USD 4.08 billion by 2030. The Drug Eluting Stents market is slated to witness prosperity owing to factors such as growing prevalence of cardiovascular diseases which can further be attributed to the increase in geriatric population wherein aging is considered to have a deleterious effect on blood vessels, growing prevalence of lifestyle disorders such as hypertension, diabetes, and obesity that are linked to affect the health of blood vessels in long term and drastically increase the probability of atherosclerosis, and the growing focus on developing newer generation of drug eluting stents in order to minimize post-procedural complications are further expected to result in the appreciable revenue growth in the drug eluting stents market during the forecast period (2024-2030).

Drug-Eluting Stents Market Dynamics:

One of the noteworthy drivers of the drug-eluting stents market is the rising prevalence of lifestyle disorders that further contribute in the development of cardiovascular diseases. Diabetes and hypertension are two of the most common indications that are linked to the pathogenesis of cardiovascular diseases. As per the figures quoted by the International Diabetes Federation, in 2022, close to 537 million adults in the 20-79 year age group were living with diabetes. Similarly, in another dataset provided by the World Health Organization (2023), on an average, raised cholesterol is estimated to result in 2.6 million deaths. High levels of cholesterol and blood sugar are linked with increased chances of the development of cardiovascular diseases as they heavily impact the vasculature supplying the myocardium. Drug-eluting stents are employed in opening up the blocked blood vessels as well as also deliver drugs at the site of stent placement in order to avoid restenosis. Therefore, the increasing prevalence of cardiovascular diseases due to surge in the number of lifestyle disorders are anticipated to drive the demand for such stents eventually leading the global drug-eluting stents market growth during the forecast period (2024-2030).

Another key factor responsible for the growth of the drug-eluting stents market is the rising geriatric population. As per the data provide by the World Health Organization in their Decade of Healthy Ageing(2020-2030) Report, the number of people aged 60 years and older will be 34% higher, increasing from one billion in 2019 to 1.4 billion in 2030. The report further stated that by 2050, the global population of the elderly will get doubled to 2.1 billion. Aging has been related to thickening of blood vessels which further impacts the elasticity of blood vessels. This acts as a major factor for the development of arteriosclerosis in the elderly population, wherein the preferred mode of treatment is the employment of drug-eluting stents. Thus, the increase in the aging population is expected to further drive the demand for drug-eluting stents owing to the effects of aging on the vasculature, ultimately bolstering the growth of the drug eluting stents market in the near future.

However, frequent product recalls and device-related complications may act as restraining factors to the drug eluting stents market growth.

The drug eluting stents market reported a short period of restraint in market growth due to the implementation of lockdown as necessary measures to break the chain of the COVID-19 infection transmission. The imposing of lockdown massively affected the supply chains and production disruptions affected the device production. Many countries segregated medical procedures based on the need for urgent medical care in order to streamline the workflow during the COVID-19 crisis and saw various medical procedures considered elective being suspended. This led to the decrease in product demand from regular levels. However, with the resumption of activities across industries including the healthcare sector, it has been uplifting for the drug eluting stents market during the forecast period from 2024-2030.

Drug-Eluting Stents Market Segment Analysis:

Drug-Eluting Stents Market by Type (Coronary Stenting and Peripheral Stenting), by Scaffold (Platinum-Chromium, Cobalt-Chromium, Nitinol, and Others), by Coating (Polymer-based Coating [Biodegradable and Non-biodegradable] and Polymer-free Coating), by Drug Type (Everomilus, Paclitaxel, and Others), by End User (Hospitals, Ambulatory Surgical Centers, and Specialty Clinics), and by Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the coating segment of the drug-eluting stents market, the polymer-coated category is projected to register a significant growth in revenue in the drug eluting stents market during the forecast period (2024-2030). This can be ascribed to the advantages associated with the drug eluting stents coated with polymer. The polymer coating on these stents release antiproliferative drugs which prevents restenosis by inhibiting intimal proliferation after stent implantation. Additionally, bioresorbable or biodegradable polymers on drug eluting stents are advantageous over the non-biodegradable ones. The biodegradable polymer coating degrades on its own after the complete release of the drug leaving behind an inert metal scaffold in place, which may improve arterial healing. Biodegradable polymer coatings are also associated with lower risk of late thrombosis compared to first generation drug eluting stents. Therefore, considering the advantages associated with biodegradable polymer coating on drug eluting stents, this product category is expected to generate considerable revenue thereby pushing the overall growth of the global drug eluting stents market during the forecast period.

North America is expected to dominate the overall Drug-Eluting Stents Market:

Among all the regions, North America is expected to lead in revenue generation in the global drug-eluting stents market. This can be ascribed to the large presence of patient pool of cardiovascular diseases which can further be attributed to the increased reliance on junk food, sedentary lifestyle among other factors, extensive coverage both by private and public health insurance providers for the stent placement procedures, as well as increasing aging population of the elderly, among other factors in the region.

One of the key factors supporting the growth of the North America drug eluting stents market is the growing prevalence of cardiovascular diseases such as the peripheral artery disease. As per the number quoted by the Centers for Disease Control and Prevention (2023), near about 6.5 million people in the age group of 40 years and older suffer from PAD in the United States. Furthermore, it has been established that PAD can further heighten the risk for developing cerebrovascular disease and coronary artery disease. The drug-coated stents such as paclitaxel-eluting stents help in mechanically opening the blocked vessels and improve blood flow in the lower limbs which further help in improving the prognosis for patients. Therefore, the rising prevalence of peripheral artery disease in the country and the extensive use of drug-eluting stents are expected to bolster the growth of the drug eluting stents market in the United States during the forecast period.

Moreover, the data provided by the Government of Canada (2023) stated that on an average, Canadians employed in full-time employment spend 68.9% of their day remaining sedentary. This type of lifestyle has been evidenced to drastically increase the risk for many of the chronic diseases including hypertension, cholesterol which may further give rise to other cardiovascular diseases such as atherosclerosis. In events like this, drug-eluting stents are then employed in the opening up the blocked vessels as part of the treatment regimen. Thus, the decrease in physical activity and increase in sedentary behavior in the Canadian population may also contribute in the growing prevalence of risk factors such as obesity and hypertension in the population, ultimately leading to the development of various cardiovascular disorders. This may act as another stimulating factor for the drug-eluting stents market in the coming years to target the potential patient population in the country.

The increasing patient population in the region further motivate manufacturers in gaining product approvals from the local regulatory bodies. For instance, in April 2022, the Canadian medical device regulatory authority body, Health Canada granted product approval to Biotronik's Orsiro drug-eluting stent for the treatment of coronary artery disease. Local product approvals help manufacturers establish credibility in individual countries and further improving product reach on a country level.

Therefore, all the factors are collectively expected to influence the demand for such stents eventually driving the growth of the North America drug eluting stents market during the forecast period.

Drug-Eluting Stents Market Key Players:

Some of the key market players operating in the drug eluting stents market includes Abbott, Medtronic, Boston Scientific Corporation, B. Braun Melsungen AG, BIOTRONIK, Cook, Terumo Corporation, Lepu Medical Technology(Beijing)Co.,Ltd, MicroPort Scientific Corporation., Balton Sp. z o.o., ENDOCOR GmbH, Eurocor Tech GmbH., Alvimedica, Biosensors International Group, Meril Life Sciences Pvt. Ltd, Translumina, Sino Medical Sciences Technology Inc, iVascular S.L.U Sahajanand Laser Technology Limited (SLTL Group)., Cardionovum GmbH., and others.

Recent Developmental Activities in Drug-Eluting Stents Market:

In September 2022, Biotronik received the regulatory approval from the US Food and Drug Administration for their Orsiro Mission bioabsorbable polymer drug-eluting stent system (BP-DES). The device is said to feature the ultrathin strut design touted as the thinnest available design available in the United States.

In June 2022, Abbott received the product approval from the US FDA for their XIENCE family of stents for one-month (for 28 days) DAPT labeling for high bleeding risk (HBR) patients in the U.S. The product has already received the CE mark approval.

In May 2022, Alvimedica received the CE mark approval for their NiTides self-expanding, drug-eluting stent aimed for treating lesions associated with peripheral artery disease in the superficial femoral arteries.

Key Takeaways from the Drug-Eluting Stents Market Report Study

Market size analysis for current drug eluting stents market size (2023), and market forecast for 5 years (2024-2030)

The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the drug eluting stents market.

Top key product/services/technology developments, mergers, acquisitions, partnerships, joint ventures happened for last 3 years

Key companies dominating the global drug eluting stents market.

Various opportunities available for the other competitor in the drug eluting stents market space.

What are the top performing segments in 2023? How these segments will perform in 2030.

Which is the top-performing regions and countries in the current drug eluting stents market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for drug eluting stents market growth in the coming future?

Target Audience who can be benefited from this Drug-Eluting Stents Market Report Study

Drug Eluting Stents products providers

Research organizations and consulting companies

Drug Eluting Stents-related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders dealing in drug eluting stents

Various end users who want to know more about the drug eluting stents market and latest technological developments in the drug eluting stents market.

Frequently Asked Questions for Drug-Eluting Stents Market:

1. What is a drug eluting stent?

A drug-eluting stent is a small mesh structure which is inserted into the artery to keep it open and also releases a medication which helps in preventing the formation of blood clots inside the stent.

2. What is the market for Global Drug Eluting Stents?

Global drug-eluting stents market was valued at USD 2.57 billion in 2023, growing at a CAGR of 8.09% during the forecast period from 2024 to 2030 to reach USD 4.08 billion by 2030.

3. What are the drivers for Global Drug Eluting Stents Market?

The Drug Eluting Stents market is slated to witness prosperity owing to factors such as growing prevalence of cardiovascular diseases which can further be attributed to the increase in geriatric population wherein aging is considered to have a deleterious effect on blood vessels, growing prevalence of lifestyle disorders such as hypertension, diabetes, and obesity that are linked to affect the health of blood vessels in long term and drastically increase the probability of atherosclerosis, and the growing focus on developing newer generation of drug eluting stents in order to minimize post-procedural complications are further expected to result in the appreciable revenue growth in the drug eluting stents market during the forecast period (2024-2030).

4. Who are the key players operating in Global Drug Eluting Stents Market?

5. Which region has the highest share in Drug Eluting Stents market?

North America is expected to dominate the overall Surgical Robotic Systems market during the forecast period, 2024 to 2030. This can be ascribed to the large presence of patient pool of cardiovascular diseases which can further be attributed to the increased reliance on junk food, sedentary lifestyle among other factors, extensive coverage both by private and public health insurance providers for the stent placement procedures, as well as increasing aging population of the elderly, among other factors in the region.

1.Drug Eluting Stents Market Report Introduction

2.Drug Eluting Stents Market Executive Summary

2.1. Scope of the Study
2.2. Market at Glance
2.3. Competitive Assessment
2.4. Financial Benchmarking

3. Regulatory Analysis

3.1. The United States
3.2. Europe
3.3. Japan
3.4. China

4. Drug Eluting Stents Market Key Factors Analysis

4.1. Drug Eluting Stents Market Drivers
- 4.1.1. Increasing Prevalence of Cardiovascular Diseases
- 4.1.2. Rising Geriatric Population
- 4.1.3. Growing Prevalence of Lifestyle Disorders
- 4.1.4. Increasing Focus on Developing New Products
4.2. Drug Eluting Stents Market Restraints and Challenges
- 4.2.1. Frequent Product Recalls
- 4.2.2. Device-Related Complications
4.3. Drug Eluting Stents Market Opportunities
- 4.3.1. Improving Product Safety
- 4.3.2. Targeting Emerging Economies for Product Launches

5. Drug Eluting Stents Market Porter's Five Forces Analysis

5.1. Bargaining Power of Suppliers
5.2. Bargaining Power of Consumers
5.3. Threat of New Entrants
5.4. Threat of Substitutes
5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Drug Eluting Stents Market

7. Drug Eluting Stents Market Layout

7.1. By Type
- 7.1.1. Coronary Stenting
- 7.1.2. Peripheral Stenting
7.2. By Scaffold
- 7.2.1. Platinum-Chromium
- 7.2.2. Cobalt-Chromium
- 7.2.3. Nitinol
- 7.2.4. Others
7.3. By Coating
- 7.3.1. Polymer-based Coating
  - 7.3.1.1. Biodegradable
  - 7.3.1.2. Non-Biodegradable
- 7.3.2. Polymer-Free Coating
7.4. By Drug Type
- 7.4.1. Everolimus
- 7.4.2. Paclitaxel
- 7.4.3. Others
7.5. By End User
- 7.5.1. Hospitals
- 7.5.2. Ambulatory Surgical Centers
- 7.5.3. Specialty Clinics
7.6. By Geography
- 7.6.1. North America
  - 7.6.1.1. North America Drug-Eluting Stents Market, by Type
  - 7.6.1.2. North America Drug-Eluting Stents Market, by Scaffold
  - 7.6.1.3. North America Drug-Eluting Stents Market, by Coating
  - 7.6.1.4. North America Drug-Eluting Stents Market, by Drug Type
  - 7.6.1.5. North America Drug-Eluting Stents Market, by End User
  - 7.6.1.6. North America Drug-Eluting Stents Market, by Country
  - 7.6.1.6.1. United States
  - 7.6.1.6.2. Canada
  - 7.6.1.6.3. Mexico
- 7.6.2. Europe
  - 7.6.2.1. Europe Drug-Eluting Stents Market, by Type
  - 7.6.2.2. Europe Drug-Eluting Stents Market, by Scaffold
  - 7.6.2.3. Europe Drug-Eluting Stents Market, by Coating
  - 7.6.2.4. Europe Drug-Eluting Stents Market, by Drug Type
  - 7.6.2.5. Europe Drug-Eluting Stents Market, by End User
  - 7.6.2.6. Europe Drug-Eluting Stents Market, by Country
  - 7.6.2.6.1. France
  - 7.6.2.6.2. Germany
  - 7.6.2.6.3. United Kingdom
  - 7.6.2.6.4. Italy
  - 7.6.2.6.5. Spain
  - 7.6.2.6.6. Russia
  - 7.6.2.6.7. Rest of Europe
- 7.6.3. Asia-Pacific
  - 7.6.3.1. Asia-Pacific Drug-Eluting Stents Market, by Type
  - 7.6.3.2. Asia-Pacific Drug-Eluting Stents Market, by Scaffold
  - 7.6.3.3. Asia-Pacific Drug-Eluting Stents Market, by Coating
  - 7.6.3.4. Asia-Pacific Drug-Eluting Stents Market, by Drug Type
  - 7.6.3.5. Asia-Pacific Drug-Eluting Stents Market, by End User
  - 7.6.3.6. Asia-Pacific Drug-Eluting Stents Market, by Country
  - 7.6.3.6.1. China
  - 7.6.3.6.2. Japan
  - 7.6.3.6.3. India
  - 7.6.3.6.4. Australia
  - 7.6.3.6.5. South Korea
  - 7.6.3.6.6. Rest of Asia Pacific
- 7.6.4. Rest of the World (RoW)
  - 7.6.4.1. RoW Drug-Eluting Stents Market, by Type
  - 7.6.4.2. RoW Drug-Eluting Stents Market, by Scaffold
  - 7.6.4.3. RoW Drug-Eluting Stents Market, by Coating
  - 7.6.4.4. RoW Drug-Eluting Stents Market, by Drug Type
  - 7.6.4.5. RoW Drug-Eluting Stents Market, by End User
  - 7.6.4.6. RoW Drug-Eluting Stents Market, by Region
  - 7.6.4.6.1. Middle East
  - 7.6.4.6.2. Africa
  - 7.6.4.6.3. South America

8. Drug-Eluting Stents Market Global Company Share Analysis - Key 3-5 Companies

9. Drug-Eluting Stents Market Company and Product Profiles

9.1. Abbott
- 9.1.1. Company Overview
- 9.1.2. Company Snapshot
- 9.1.3. Financial Overview
- 9.1.4. Product Listing
- 9.1.5. Entropy
9.2. Medtronic
- 9.2.1. Company Overview
- 9.2.2. Company Snapshot
- 9.2.3. Financial Overview
- 9.2.4. Product Listing
- 9.2.5. Entropy
9.3. Boston Scientific Corporation
- 9.3.1. Company Overview
- 9.3.2. Company Snapshot
- 9.3.3. Financial Overview
- 9.3.4. Product Listing
- 9.3.5. Entropy
9.4. B. Braun Melsungen AG
- 9.4.1. Company Overview
- 9.4.2. Company Snapshot
- 9.4.3. Financial Overview
- 9.4.4. Product Listing
- 9.4.5. Entropy
9.5. BIOTRONIK
- 9.5.1. Company Overview
- 9.5.2. Company Snapshot
- 9.5.3. Financial Overview
- 9.5.4. Product Listing
- 9.5.5. Entropy
9.6. Cook
- 9.6.1. Company Overview
- 9.6.2. Company Snapshot
- 9.6.3. Financial Overview
- 9.6.4. Product Listing
- 9.6.5. Entropy
9.7. Terumo Corporation
- 9.7.1. Company Overview
- 9.7.2. Company Snapshot
- 9.7.3. Financial Overview
- 9.7.4. Product Listing
- 9.7.5. Entropy
9.8. Lepu Medical Technology(Beijing)Co.,Ltd
- 9.8.1. Company Overview
- 9.8.2. Company Snapshot
- 9.8.3. Financial Overview
- 9.8.4. Product Listing
- 9.8.5. Entropy
9.9. Microport Scientific Corporation
- 9.9.1. Company Overview
- 9.9.2. Company Snapshot
- 9.9.3. Financial Overview
- 9.9.4. Product Listing
- 9.9.5. Entropy
9.10. Balton Sp.z.o.o
- 9.10.1. Company Overview
- 9.10.2. Company Snapshot
- 9.10.3. Financial Overview
- 9.10.4. Product Listing
- 9.10.5. Entropy
9.11. ENDOCOR GmbH
- 9.11.1. Company Overview
- 9.11.2. Company Snapshot
- 9.11.3. Financial Overview
- 9.11.4. Product Listing
- 9.11.5. Entropy
9.12. Eurocor Tech GmbH
- 9.12.1. Company Overview
- 9.12.2. Company Snapshot
- 9.12.3. Financial Overview
- 9.12.4. Product Listing
- 9.12.5. Entropy
9.13. Alvimedica
- 9.13.1. Company Overview
- 9.13.2. Company Snapshot
- 9.13.3. Financial Overview
- 9.13.4. Product Listing
- 9.13.5. Entropy
9.14. Biosensors International Group
- 9.14.1. Company Overview
- 9.14.2. Company Snapshot
- 9.14.3. Financial Overview
- 9.14.4. Product Listing
- 9.14.5. Entropy
9.15. Meril Life Sciences Pvt. Ltd
- 9.15.1. Company Overview
- 9.15.2. Company Snapshot
- 9.15.3. Financial Overview
- 9.15.4. Product Listing
- 9.15.5. Entropy
9.16. Translumina
- 9.16.1. Company Overview
- 9.16.2. Company Snapshot
- 9.16.3. Financial Overview
- 9.16.4. Product Listing
- 9.16.5. Entropy
9.17. Sino Medical Sciences Technology Inc
- 9.17.1. Company Overview
- 9.17.2. Company Snapshot
- 9.17.3. Financial Overview
- 9.17.4. Product Listing
- 9.17.5. Entropy
9.18. iVascular S.L.U
- 9.18.1. Company Overview
- 9.18.2. Company Snapshot
- 9.18.3. Financial Overview
- 9.18.4. Product Listing
- 9.18.5. Entropy
9.19. Sahajanand Laser Technology Limited (SLTL Group)
- 9.19.1. Company Overview
- 9.19.2. Company Snapshot
- 9.19.3. Financial Overview
- 9.19.4. Product Listing
- 9.19.5. Entropy
9.20. Cardionovum GmbH
- 9.20.1. Company Overview
- 9.20.2. Company Snapshot
- 9.20.3. Financial Overview
- 9.20.4. Product Listing
- 9.20.5. Entropy